Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon

RecruitingOBSERVATIONAL

Enrollment

120

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Chronic Hepatitis B

Interventions

DRUG

PEG-IFN-α

chronic hepatitis B (CHB) who were continuously treated with pegylated interferon (PEG-IFN - α) for more than 24 weeks

Trial Locations (1)

RECRUITING

Beijing Ditan Hospital, Capital Medical University, Beijing

All Listed Sponsors

lead

Minghui Li

OTHER_GOV